ATE525384T1 - Varianten des hepatitisvirus - Google Patents

Varianten des hepatitisvirus

Info

Publication number
ATE525384T1
ATE525384T1 AT01937697T AT01937697T ATE525384T1 AT E525384 T1 ATE525384 T1 AT E525384T1 AT 01937697 T AT01937697 T AT 01937697T AT 01937697 T AT01937697 T AT 01937697T AT E525384 T1 ATE525384 T1 AT E525384T1
Authority
AT
Austria
Prior art keywords
hcv
variants
methods
expression vectors
polynucleotides
Prior art date
Application number
AT01937697T
Other languages
German (de)
English (en)
Inventor
Charles M Rice
Keril Blight
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/576,989 external-priority patent/US7049428B1/en
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of ATE525384T1 publication Critical patent/ATE525384T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Catalysts (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01937697T 2000-05-23 2001-05-23 Varianten des hepatitisvirus ATE525384T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/576,989 US7049428B1 (en) 1998-03-04 2000-05-23 HCV variants
PCT/US2001/016822 WO2001089364A2 (en) 2000-05-23 2001-05-23 Hcv variants

Publications (1)

Publication Number Publication Date
ATE525384T1 true ATE525384T1 (de) 2011-10-15

Family

ID=24306833

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01937697T ATE525384T1 (de) 2000-05-23 2001-05-23 Varianten des hepatitisvirus

Country Status (9)

Country Link
EP (1) EP1296998B1 (https=)
JP (2) JP4095303B2 (https=)
AT (1) ATE525384T1 (https=)
AU (1) AU2001263407B9 (https=)
CA (1) CA2409873C (https=)
DK (1) DK1296998T3 (https=)
ES (1) ES2373642T3 (https=)
IL (3) IL152671A0 (https=)
WO (1) WO2001089364A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235394B1 (en) 1995-08-29 2007-06-26 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
MXPA03005638A (es) 2000-12-22 2004-04-05 Boehringer Ingelheim Ca Ltd Auto replicacion de la molecula de arn de virus de la hepatitis c.
EP1423522A2 (en) 2001-01-23 2004-06-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus replicons and replicon enhanced cells
ES2346717T3 (es) * 2002-03-11 2010-10-19 Lab 21 Limited Metodo y composiciones para identificar y caracterizar la hepatitis c.
WO2003089672A1 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Hepatitis c virus assay systems
KR100502864B1 (ko) * 2002-10-09 2005-07-22 (주)팬바이오넷 Ｃ형 간염바이러스의 복제 정량 리플리콘, 이를 포함하는세포주, 및 상기 세포주를 이용한 ｈｃｖ 저해제의 탐색방법
US7455969B2 (en) 2002-11-13 2008-11-25 Washington University Highly permissive cell lines for hepatitis C virus RNA replication
US7807455B2 (en) 2003-02-13 2010-10-05 Merck Sharp & Dohme Corp. Method to confer cell culture replication activity to different Hepatitis C virus isolates
CN1856503A (zh) * 2003-09-22 2006-11-01 株式会社绿多肽 来源于c型肝炎病毒的肽
US8354518B2 (en) 2003-11-05 2013-01-15 Merck Sharp & Dohme Corp. HCV replicons containing NS5B from genotype 2B
KR100894150B1 (ko) * 2004-06-25 2009-04-22 가부시끼가이샤 센단세메이가가꾸겐큐죠 신규한 배열을 가진 ｈｃｖ ｒｎａ
GB0421908D0 (en) 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
EP2151495A4 (en) * 2007-04-27 2010-06-02 Advanced Life Science Inst Inc HCV GENE
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
AU2008338803B2 (en) * 2007-11-26 2015-02-05 Glaxosmithkline Biologicals S.A. Methods of generating alphavirus particles
EP2558117A4 (en) * 2010-04-12 2013-11-13 Viracine Therapeutics Corp EXPRESSION OF POSITIVELY SENSING INTRODUCING RNA VIRUSES AND USES THEREOF
US9353423B2 (en) 2012-11-07 2016-05-31 Gilead Sciences, Inc. HCV genotype 6 replicons
CN112225783B (zh) * 2020-09-16 2021-08-31 东莞市朋志生物科技有限公司 Hcv重组抗原及其突变体

Also Published As

Publication number Publication date
IL176731A (en) 2009-12-24
DK1296998T3 (da) 2011-12-12
AU2001263407B2 (en) 2006-12-07
WO2001089364A2 (en) 2001-11-29
WO2001089364A3 (en) 2003-01-23
AU2001263407B9 (en) 2007-05-24
JP2007143553A (ja) 2007-06-14
IL152671A (en) 2009-09-01
JP2003533232A (ja) 2003-11-11
IL152671A0 (en) 2003-06-24
ES2373642T3 (es) 2012-02-07
WO2001089364A9 (en) 2003-07-10
CA2409873A1 (en) 2001-11-29
EP1296998A2 (en) 2003-04-02
IL176731A0 (en) 2006-10-31
EP1296998A4 (en) 2009-01-28
EP1296998B1 (en) 2011-09-21
JP4095303B2 (ja) 2008-06-04
CA2409873C (en) 2013-01-08
AU6340701A (en) 2001-12-03

Similar Documents

Publication Publication Date Title
ATE525384T1 (de) Varianten des hepatitisvirus
Becher et al. Genetic diversity of pestiviruses: identification of novel groups and implications for classification
ES2020152A4 (es) Diagnosticos y vacunas para nanbv.
AU4203201A (en) Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
Kang et al. Establishment and characterization of two new cell lines derived from flounder, Paralichthys olivaceus (Temminck & Schlegel)
HUP0000992A2 (hu) Sejttenyészetben szaporodni képes, géntechnológiailag módosított, fertőző nyálkatömlő-betegséget okozó vírus (IBDV) mutánsai
DK1554301T3 (da) Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
TR199901602T2 (xx) Serin proteazlar�n ve �zel olarak hepatit C vir�s� NS3 proteaz�n�n inhibit�rleri.
WO2005030800A3 (en) Oligonucleotide analog and method for treating flavivirus infections
RU2009145104A (ru) Флавивирус с двухкомпонентным геномом и его использование
PL373992A1 (en) Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
TW200502246A (en) Vaccine
DE60005390D1 (de) Hcv ns3 proteaseinhibitoren
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
EP1439856A4 (en) RECOMBINANT TOLLWOOD VACCINES AND METHOD FOR THEIR PREPARATION AND USE
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
CN101748151B (zh) 一种重组人丙肝病毒抗原腺病毒载体及其应用
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
TW200509964A (en) VP1 of foot-and-mouth disease virus
TR200102168T2 (tr) BHV-1 geni silinmiş virüs aşısı.
AU2001249928A1 (en) Full-length gb virus c (hepatitis g virus) rna transcripts are infectious in primary cd4 positive t cells and methods of treating hiv
CY1107374T1 (el) Εμβολιο ιχθυος εναντι της piscirickettsia salmonis
AR035809A1 (es) Cromosomas artificiales que comprenden secuencias de ehv
Parker Studies of the capsid determinants of canine parvovirus host range and mechanisms of virus uptake and infectious entry into cells in vitro

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties